Israel (IL)

What do we know about dynamic glucose-enhanced (DGE) MRI and how close is it to the clinics? Horizon 2020 GLINT consortium report (2022) Kim M, Eleftheriou A, Ravotto L, Weber B, Rivlin M, Navon G, Capozza M, et al. Journal article, Review article Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. (2022) Elhai M, Sritharan N, Boubaya M, Balbir-Gurman A, Siegert E, Hachulla E, de Vries-Bouwstra J, et al. Journal article Observation of interband Berry phase in laser-driven crystals (2022) Uzan-Narovlansky AJ, Faeyrman L, Shames S, Narovlansky V, Xaio J, Arusi-Parpar T, Kneller O, et al. Conference contribution Correction: Characteristics of people with epilepsy in three Eastern African countries - a pooled analysis. (2022) Stelzle D, Kaducu J, Schmidt V, Welte TM, Ngowi BJ, Matuja W, Escheu G, et al. Journal article, Erratum Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. (2022) Zanatta E, Huscher D, Ortolan A, Avouac J, Airo P, Balbir-Gurman A, Siegert E, et al. Journal article Guidelines for DC preparation and flow cytometry analysis of mouse nonlymphoid tissues (2022) Probst HC, Stoitzner P, Amon L, Backer RA, Brand A, Chen J, Clausen BE, et al. Journal article Preparation and filling of small oval root canals: influence of file system and sealer. (2022) Eichelsdoerfer K, Buettner K, Lohbauer U, Petschelt A, Metzger Z, Ebert J Journal article Prognostic Significance of Nonobstructive Left Main Coronary Artery Disease in Patients With and Without Diabetes: Long-Term Outcomes From the CONFIRM Registry (2022) Lee J, Shaikh K, Nakanishi R, Gransar H, Achenbach S, Al-Mallah MH, Andreini D, et al. Journal article Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. (2022) Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, Bauer JM, et al. Journal article Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article